

Achieving Success in IgAN & FSGS – Additional Resources

Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial

Heerspink HJL, Radhakrishnan J, Alpers CE, et al; PROTECT Investigators. Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial. *Lancet*. 2023;401(10388):1584-1594. doi:10.1016/S0140-6736(23)00569-X

Link: [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736\(23\)00569-X/fulltext](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)00569-X/fulltext)

Long-term outcomes in IgA nephropathy

Pitcher D, Braddon F, Hendry B, et al. Long-term outcomes in IgA nephropathy. *Clin J Am Soc Nephrol*. 2023;18(6):727-738. doi:10.2215/CJN.000000000000135

Link: https://journals.lww.com/cjasn/Fulltext/2023/06000/Long_Term_Outcomes_in_IgA_Nephropathy.9.aspx

An outcomes-based definition of proteinuria remission in focal segmental glomerulosclerosis

Troost JP, Trachtman H, Nachman PH, et al. An outcomes-based definition of proteinuria remission in focal segmental glomerulosclerosis. *Clin J Am Soc Nephrol*. 2018;13(3):414-421. doi:10.2215/CJN.04780517

Link: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5967666/>

Focal segmental glomerulosclerosis, risk factors for end stage kidney disease, and response to immunosuppression

Forster BM, Nee R, Little DJ, et al. Focal segmental glomerulosclerosis, risk factors for end stage kidney disease, and response to immunosuppression. *Kidney360*. 2020;2(1):105-113. doi:10.34067/KID.0006172020

Link: <https://pubmed.ncbi.nlm.nih.gov/35368810/>

Oxford Classification of IgA nephropathy 2016: an update from the IgA Nephropathy Classification Working Group

Trimarchi H, Barratt J, Cattran DC, et al; IgAN Classification Working Group of the International IgA Nephropathy Network and the Renal Pathology Society; Conference Participants. Oxford

Classification of IgA nephropathy 2016: an update from the IgA Nephropathy Classification Working Group. *Kidney Int.* 2017;91(5):1014-1021. doi:10.1016/j.kint.2017.02.003

Link: [https://www.kidney-international.org/article/S0085-2538\(17\)30101-1/fulltext](https://www.kidney-international.org/article/S0085-2538(17)30101-1/fulltext)

KDIGO 2021 clinical practice guideline for the management of glomerular diseases

Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group. KDIGO 2021 clinical practice guideline for the management of glomerular diseases. *Kidney Int.* 2021;100(4S):S1-S276. doi:10.1016/j.kint.2021.05.021

Link: [https://www.kidney-international.org/article/S0085-2538\(21\)00562-7/fulltext](https://www.kidney-international.org/article/S0085-2538(21)00562-7/fulltext)

Sparsentan: first approval

Syed YY. Sparsentan: first approval. *Drugs.* 2023;83(6):563-568. doi:10.1007/s40265-023-01864-x

Link: <https://link.springer.com/article/10.1007/s40265-023-01864-x>